France
· Delayed Price · Currency is EUR Transgene Statistics
Total Valuation
Transgene has a market cap or net worth of EUR 102.69 million. The enterprise value is 124.15 million.
| Market Cap | 102.69M |
| Enterprise Value | 124.15M |
Important Dates
The last earnings date was Thursday, November 7, 2024.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Transgene has 131.99 million shares outstanding. The number of shares has increased by 1.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 131.99M |
| Shares Change (YoY) | +1.17% |
| Shares Change (QoQ) | -0.42% |
| Owned by Insiders (%) | 70.04% |
| Owned by Institutions (%) | 1.10% |
| Float | 34.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.12 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.42 |
| EV / Sales | 19.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.20 |
Financial Position
The company has a current ratio of 1.57
| Current Ratio | 1.57 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.95 |
| Interest Coverage | -46.46 |
Financial Efficiency
Return on equity (ROE) is -214.69% and return on invested capital (ROIC) is -54.54%.
| Return on Equity (ROE) | -214.69% |
| Return on Assets (ROA) | -38.85% |
| Return on Capital (ROIC) | -54.54% |
| Revenue Per Employee | 44,479 |
| Profits Per Employee | -156,925 |
| Employee Count | 141 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.48% in the last 52 weeks. The beta is 0.73, so Transgene's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -46.48% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 27.11 |
| Average Volume (20 Days) | 44,084 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Transgene had revenue of EUR 6.49 million and -22.91 million in losses. Loss per share was -0.23.
| Revenue | 6.49M |
| Gross Profit | -22.95M |
| Operating Income | -31.17M |
| Pretax Income | -22.91M |
| Net Income | -22.91M |
| EBITDA | -30.04M |
| EBIT | -31.17M |
| Loss Per Share | -0.23 |
Balance Sheet
The company has 15.32 million in cash and 36.78 million in debt, giving a net cash position of -21.46 million or -0.16 per share.
| Cash & Cash Equivalents | 15.32M |
| Total Debt | 36.78M |
| Net Cash | -21.46M |
| Net Cash Per Share | -0.16 |
| Equity (Book Value) | -616,000 |
| Book Value Per Share | -0.01 |
| Working Capital | 6.95M |
Cash Flow
In the last 12 months, operating cash flow was -35.54 million and capital expenditures -3.27 million, giving a free cash flow of -38.81 million.
| Operating Cash Flow | -35.54M |
| Capital Expenditures | -3.27M |
| Free Cash Flow | -38.81M |
| FCF Per Share | -0.29 |
Margins
| Gross Margin | n/a |
| Operating Margin | -480.04% |
| Pretax Margin | -352.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -597.67% |
Dividends & Yields
Transgene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.17% |
| Shareholder Yield | -1.17% |
| Earnings Yield | -29.11% |
| FCF Yield | -37.80% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Transgene has an Altman Z-Score of -3.44. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.44 |
| Piotroski F-Score | n/a |